The influence of riboflavin photochemistry on plasma coagulation factors

Transfusion and Apheresis Science

Volumn 41, Issue 3, 2009, Pages 199-204

  Larrea, Luis ^a   Calabuig, María ^a   Roldán, Vanesa ^b   Rivera, José ^b   Tsai, Han Mou ^c   Vicente, Vicente ^b   Roig, Roberto ^a  

^a Centro de Transfusion de la Comunidad Valenciana   (Spain)

^b HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Coagulation factors; Pathogen reduction; Plasma; Riboflavin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; FRESH FROZEN PLASMA; PROTEIN C; PROTEIN S; PROTHROMBIN; RIBOFLAVIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; HUMAN; LIGHT; PHOTOCHEMISTRY; PROTEIN ANALYSIS;

BLOOD COAGULATION FACTORS; BLOOD PROTEINS; DISINFECTION; HUMANS; LIGHT; PHOTOCHEMICAL PROCESSES; PHOTOSENSITIZING AGENTS; RIBOFLAVIN;

EID: 71549147205     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2009.09.006     Document Type: Article

References (27)

1. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 35 (2006) 83-90
2. Bryant B.J., and Klein H.G. Pathogen inactivation. The definitive safeguard for the blood supply. Arch Pathol Lab Med 13 (2007) 719-733
3. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma what is its contribution to blood safety?. Transfusion 43 (2003) 1322-1329
4. Sandler S.G. The case for pathogen inactivation of blood components. Curr Opin Hematol 12 (2005) 471-472
5. Allain J.P., Bianco C., Blachman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 19 (2005) 110-126
6. Pelletier J.P.R., Transue S., and Zinder E.L. Pathogen inactivation techniques. Best Pract Research Clin Haematol 19 (2006) 205-242
7. Ruane P., Edrich R., Gampp D., Keil S., Leonard L., and Goodrich R. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44 (2004) 877-885
8. Goodrich R.P., Li J., Edrich R., and Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 35 (2006) 5-17
9. Goodrich RP, Edrich RA. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine. In: Silva E, Edwards AM, editors. Comprehensive series in photochemistry and photobiology, vol. 6, flavins: photochemistry and photobiology, Cambridge, UK: Royal Society of Chemistry; 2006.
10. Cardo L.J., Salata J., Mendez J., Reddy H., and Goodrich R.P. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrations using riboflavin and light. Vox Sang 37 (2007) 131-137
11. Cardo L., Rentas F., Ketchum L., Salata J., Harman R., Melvin W., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and light. Vox Sang 90 (2006) 85-91
12. Fast L.D., Dileone G., Li J., and Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 46 (2006) 642-648
13. Tsai H., Chandler W., Sarode R., Hoffman R., Jelacic S., Habeeb R.L., et al. Von Willebrand factor and Von Willebrand factor - cleaving metalloprotease activity in Escherichia coli 0157: H7 - associated hemolytic uremic syndrome. Pediatr Res 49 (2001) 5
14. European Committee on Blood Transfusion. Guide to the preparation, use and quality assurance of blood components. 14th ed.; 2008.
15. Hellstern P., and Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 107 Suppl. 1 (2002) S3-S8
16. Rosen S., and Cason M.C. Determination of factor VIII activity in plasma and concentrates: comparison between methods. Am Clin Lab (2002) 32-37
17. Buytaert-Hoefen K., Gampp D., Edrich R., Hendrix B., and Goodrich R. Mirasol pathogen treated frozen plasma maintains protein quality. Transfusion 47 3S (2007) SP88
18. Beeck H., and Hellstern P. In vitro characterization of solvent/detergent treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74 Suppl. 1 (1998) 219-223
19. Hellstern P., Sachse H., Schwinn H., and Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63 (1992) 178-185
20. Lutze G., and Hartung K.J. Gerinnungsfaktoren-Aktivitäts-und Konzentrationsbestimmungen in konventionellen und virusinaktivierten gerinnungsaktiven Plasmen. Krankenhauspharmazie 15 (1994) 517-522
21. Leebeek F.W.G., Schipperus M.R., and van Vliet H.H.D.M. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion 39 (1999) 1150-1151
22. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., and Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
23. Garwood M., Cardigan R.A., Drummond O., Hornsey V.S., Turner C.P., Young D., et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 43 (2003) 1238-1247
24. Schlenke P., Hervig T., Isola H., Wiesel M.L., Kientz D., Pinkoski L., et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 48 (2008) 697-705
25. Allford S.L., Harrison P., Lawrie A.S., MacKie I.J., and Machin S.J. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 111 (2000) 1215-1222
26. Kiss J.E. Randomized clinical trials in thrombotic thrombocytopenic purpura: where do we go from here?. Transfusion 46 (2006) 1659-1662
27. Adcock D.M., Bethel M., and Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 32 (2006) 472-479